TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of SGN-CD48A in Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MM requiring systemic therapy (per the International Myeloma Working Group \[IMWG\])~* Patients must not have other therapeutic options known to provide clinical benefit in MM available to them. Prior lines of therapy must include at least a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.~* Measureable disease, as defined by at least one of the following: serum M protein 0.5 g/dL or higher, urine M protein 200 mg/24 hour or higher, and serum immunoglobulin free light chain 10 mg/dL or higher and abnormal serum immunoglobulin kappa lambda free light chain ratio~* Adequate hematologic, renal, and hepatic function~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Life expectancy greater than 3 months~* A negative pregnancy test (for females of childbearing potential)~* Patients must provide written consent~Exclusion Criteria:~* Pre-existing peripheral neuropathy Grade 2 or higher~* History of malignancy other than MM within the past 3 years~* Active cerebral/meningeal disease related to the underlying malignancy~* Uncontrolled Grade 3 or higher infection~* Known to be positive for HIV or hepatitis B, or known to have active hepatitis C infection~* Previous allogeneic stem cell transplant~* History of cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms consistent with congestive heart failure within the last 6 months~* Treatment with any known P-gp inducers/inhibitors or strong CYP3A inhibitors within 14 days prior to the first dose of study drug~* Prior antitumor therapy that is not completed at least 4 weeks prior to first dose of study drug, or at least 2 weeks if progressing. Prior CAR T-cell therapy must be completed 8 weeks before first dose of study drug.~* Females who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGN-CD48A (Type: EXPERIMENTAL): SGN-CD48A

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent and the willingness and ability to comply with all aspects of study requirements~2. Male~3. Inpatients ≥ 18 years of age with an indwelling catheter in place for at least 5 days with a plan for removal~Exclusion Criteria:~1. Patients planned for discharge with an indwelling catheter in place~2. Patients unable to report urinary symptoms accurately~3. Patients with hyper-sensitivity or allergic reaction to Betadine, iodine, shellfish or other related compounds~4. Clinical signs or symptoms of urinary tract infection at the time of consent~5. Patients currently being treated for UTI~6. Patients currently taking any antibiotic medication, other than vancomycin, linezolid, daptomycin, clindamycin, or metronidazole.~7. Patients already taking medications known to potentially irritate the bladder, such as, but not limited to, cyclophosphamide, ifosfamide, and other chemotherapeutic agents~8. Patients with history of bladder cancer, pelvic radiation or interstitial cystitis~9. Patients unable to comply with study requirements~10. Any other condition which, per investigators' judgment, may increase patient risk and/or impede the reliability of study data

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Povidone-Iodine Irrigation (Type: EXPERIMENTAL): Bladder irrigation with 2% povidine-iodine irrigation immediately prior to catheter removal
- Standard of Care (Type: NO_INTERVENTION): Catheter removal with no bladder irrigation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the ISL unit at Melrose Institute~* Diagnosed with an eating disorder (Anorexia Nervosa, Bulimia Nervosa or Eating Disorder Not Otherwise Specified)~  1. For ED-DMT1 group: Diagnosis of an eating disorder AND diagnosis of type 1 diabetes.~ 2. For ED/only group: Diagnosis of an eating disorder AND no history/diagnosis of type 1 or type 2 diabetes.~* Female.~* At least 14 years of age.~* Able to provide informed consent.~  1. If the potential participant's age is at least 18 years she must be able to provide informed consent.~ 2. If the potential participant is less than 18 years she must have a parent or guardian able and willing to provide written informed consent on the participant's behalf. In addition, the participant must be willing to sign a consent on her own behalf.~* Participants must be able and willing to utilize the CGM system and perform required calibrations using self-monitored blood glucose.~Exclusion Criteria:~* Male.~* Age \< 14 years.~* History of self-injurious behavior that the senior clinician feels precludes participation.~* Unable to understand the study protocol.~* Unwilling to follow the study protocol.~* Participation in any competing research study.~* Planned ISL admission for \<4 days.~* Pregnant.~* Not able to communicate in English.~* Regular use of acetaminophen or acetaminophen containing medications and not able to modify their medication to a non-acetaminophen based medication.

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ED-DMT1 and ED/only (Type: None): Eating Disorder and Type 1 Diabetes and only an Eating Disorder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study to Support Fetal Heart Rate and Uterine Contraction for Preterm Labor in Singleton and Multiple Pregnancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* She is \>=24weeks 0days but less than 36 completed weeks, with a singleton pregnancy or \>=34weeks 0days with a multiple pregnancy and has been admitted to the Labor and Delivery Unit~* She is in the latent phase of spontaneous labor, or has been admitted for induction of labor~* She has given her informed consent to participate as a subject~* She has none of the exclusion criteria~Exclusion Criteria:~* Known major fetal malformation or chromosome abnormality~* Involvement in another clinical trial currently or previously in this pregnancy~* Medical or obstetric problem that would preclude the use of abdominal electrodes (e.g., skin eruptions, sensitivity to adhesives)~* Significant medical or obstetric problem that in the investigator's opinion would make the woman incapable of taking part in the study

- Gender: FEMALE
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion:~* COVID-19+ in past 14 days~* Platelets \> 100,000~* eGFR \> 30ml/min~Exclusion:~* Hospitalized~* Contradiction/ other indication for anti-coagulation~* Pregnancy~* Active cancer

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Apixaban 2.5mg (Type: ACTIVE_COMPARATOR): Anticoagulation: prophylactic dose Apixaban 2.5mg po bid
- Apixaban 5mg (Type: ACTIVE_COMPARATOR): Anticoagulation: therapeutic dose Apixaban 5.0mg po bid
- Aspirin (Type: ACTIVE_COMPARATOR): Antiplatelet agent: low dose aspirin 81mg po qd
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* Diagnostic and Statical Manual-Revision 4 (DSM-IV) diagnosis of current MDD based on the Structured Clinical Interview for Depression (SCID)~* Duration of major depressive disorder (MDD) at least 4 weeks at baseline~* Hospital discharge for an acute coronary syndrome 4 to 24 weeks prior to baseline~* No coronary artery bypass (CABG) surgery during or since the admission for the index event, and no plan for CABG during the next 4 months after baseline~* Stable coronary artery disease (CAD) based on physician's clinical judgement~* Provision of informed consent~Exclusion Criteria~* Significant cognitive problems (Mini-mental Status Exam, MMSE \< 24) Structured Clinical Interview for Depression (SCID) documented bipolar disorder or use of lithium or anticonvulsants (e.g. tegretol, depakene, neurontin) for mood disorder~* MINI International Neuropsychiatric Interview (MINI) documented major depression with psychotic features~* MINI documented current or recent (within 12 months) substance abuse or dependence~* Serious suicide risk based on clinical judgment~* Currently taking antidepressants (including St. John's Wort)~* Absence of response to a previous adequate trial of citalopram~* Lifetime evidence of citalopram intolerance or lifetime evidence of intolerance to two or more other SSRIs~* 2 or more previous unsuccessful trials of treatment for the current depressive episode~* Depression due to a general medical condition based on clinical judgment (e.g., clinical hypothyroidism)~* Cold, flu or other infection or dental work (including teeth cleaning) in 14 days before baseline~* Use of antibiotics or steroids (other than topical steroids) in 14 days before baseline~* Participation in any randomized clinical trial~* Inability to speak French or English~* Investigator's judgement that patient is unable/unwilling to comply with study regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Bronchoscopy in Early Lung Cancer Screening of High Risk Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is over 40 years in age and is a heavy cigarette smoker.(smoking index is over 400)~* Patient has been coughing irritably for 2-3 weeks with a failed treatment and without obvious causes.~* The nature of cough changes in a patient who has chronic respiratory disease.~* Patient has blood-stained sputum persistently or repeatedly without obvious causes.~Patient will be included if accorded with any item of above.~Exclusion Criteria:~* Patient has dysrhythmia or cardiovascular disease that poses a risk during exercise.~* Patient has uncontrollable hypertension (SBP \> 180mmHg).~* Patient has severe organ dysfunction (shock, severe hepatic and renal dysfunction, massive hemorrhage of upper gastrointestine, diffuse intravascular coagulation(DIC) and massive hemoptysis,etc).~* Patient has blood coagulation disorders (PT\>2 times the upper limit of normal(ULN) or Platelet(PLT)\<50000/ul）.~* Patient has severe dyspnea.~* Patient is allergic to local anesthetic.~* Patient is unable to provide informed consent.~* Patient is not an appropriate candidate for or is unable to tolerate flexible bronchoscopy procedures.~* Patient has any disease or condition that interferes with completion of initial or follow-up assessments of the effectiveness endpoints.~* Patient has demonstrated unwillingness or inability to complete screening or baseline data collection procedures.~* Patient participated in a study of an investigational drug or device within the past 30 days prior to participation in this study, or is currently participating in another clinical study.~* Patient has pulmonary lesions suspected to be cancer from CT images.~* Female patient of childbearing potential has a positive result from a pregnancy test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fluorescence/Narrow Band Bronchoscopy (Type: None): All patients in the group are examined by Fluorescence Bronchoscopy and Narrow Band Bronchoscopy to make a early detection of lung cancer.
- Routine Bronchoscopy (Type: None): All patients in this group are examined by routine bronchoscopy to make a early detection of lung cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Women With Endocrine and Reproductive-Related Conditions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* Inclusion Criteria:~* Subjects aged 1-85 with reproductive endocrine related conditions.~* Young women, women of reproductive age, and older women are the focus of this protocol.~* Girls with reproductive disorders under the age of 18 will be studied and their assent will be obtained if possible along with the consent of their parent/guardian.~* Reproductive disorders of men will be included.~Exclusion Criteria:~* Pregnant women over 23 weeks will be excluded, since there are no on-campus prenatal or neonatal facilities. If we see patients in consultation after 23 weeks, as is our practice, we will provide a report to the referring PI on that protocol as well as the patient's personal obstetrician. We do not provide long term obstetrical care.~* Patients specifically requesting in vitro fertilization will not be considered candidates and will not be seen under this protocol. These patients may be seen for a consultation, but will be referred for these services outside of the NIH.~* Pregnant patients requiring fetal surgery will be excluded since there are no on-campus neonatal facilities.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Children (Type: None): with reproductive disorders
- Men (Type: None): with reproductive disorders
- Woman (Type: None): with reproductive disorders

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Endometrial Coculture (AECCT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women undergoing IVF at CRMI~* Age ≤ 38 years~* Poor ovarian reserve with antral follicle count less than 6 follicles, cycle day 2/3 FSH \> 12 ng/ml, AMH \< 0.5 ng/ml~Exclusion Criteria:~* Healthy women undergoing IVF with male factor, severe endometriosis, or tubal factor infertility~* Donor patients~* Contraindications for the use of gonadotropins (i.e. pregnancy, lactation, undiagnosed vaginal bleeding or ovarian cysts)~* Recent or current medical conditions where the patient is not medically stable to undergo stimulation or egg retrieval, HIV infection, diabetes, cardiovascular disease, gastrointestinal, hepatic disease, renal or pulmonary disease.~* Any patient who is not a candidate for IVF

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: t

Study Arms:
- No AECC (Type: PLACEBO_COMPARATOR): Routine procedures without AECC
- AECC (Type: EXPERIMENTAL): Endometrial biopsy and Autologous endometrial coculture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ischemic Foot Ulcers: Is Intervention Better Than Wound Care Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject (male or non-pregnant female) must be greater than or equal to 18 years of age~* Ischemic ulcer of foot present~* An ankle-brachial index (ABI) of 0.4 to 0.8 or monophasic-biphasic waveforms on pulse volume recordings. (If the subject is diabetic or has renal failure, with incompressible vessels, a toe brachial index of 0.4 to 0.8 is required.)~* Signed informed consent~Exclusion Criteria:~* Severe ischemia as defined by advanced gangrene, an ABI of less then or equal to 0.3 and monophasic waveforms on pulse volume recording~* Advanced renal insufficiency, defined as serum creatinine greater than or equal to 3 mg/dl~* Absolute contraindication to contrast media, as determined by the investigator~* Unwilling or unable to provide informed consent or return for required follow-up evaluations.~* Previous enrollment in this clinical study~* Concurrent participation in another clinical research study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Group I (Type: NO_INTERVENTION): 1. Wound Care (group 1)--Best standard wound care with aggressive debridement
- Group 2 (Type: ACTIVE_COMPARATOR): 2. Endovascular Intervention + Wound Care (group 2)--Best standard wound care in combination with endovascular revascularization~Endovascular revascularization is the intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Visual Function in Ophthalmic Disorders Using Virtual Visual Field Analysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with retina, glaucoma and neuroophthalmic disorders~* Patients with normal eye exams to act as controls~* Must be able to comprehend instructions and perform visual fields~Exclusion Criteria:~* Patients \<18years old~* Patients unable to comprehend visual field instructions or unwilling to participate~* Patients lacking a complete clinical file or lacking a specific diagnosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Neurology patients (Type: None): Any patients with neurological disorders
- Glaucoma patients (Type: None): Any patients with chronic open angle and chronic angle closure glaucoma of all stages
- Retina patients (Type: None): Any patients with known retinal conditions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Patient inclusion criteria:~* Elective vascular surgery~* Any of the following co morbidities~  * Diabetes~ * Angina~ * Congestive heart failure~ * A serum creatinine above 176 mmol/l~* All patients must be on stable dose of oral metoprolol (≥ 30 days)~* Age ≥ 20 years and ≤ 80 years~* Written informed consent to participate to the study~Patient exclusion criteria:~* Inability to understand the study protocol~* Prior gastric surgery or small bowel resection~* Pacemaker ( since it precludes the measurement of ST changes)~* Malabsorption syndromes~* Body Mass Index \< 18 and \> 35~* Any patient with suspected of diagnosed Cerebral vascular disease. (We chose to exclude CVA patients due to the ongoing controversy about the increased incidence of stroke in patients have surgery and who are taking beta-blockers.)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Metoprolol oral dose or Placebo infusion (Type: ACTIVE_COMPARATOR): None
- Esmolol infusion or Placebo oral dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues